Samsung Display Commercializes New, Variable Refresh Rate Technology for Increasing Smartphone Power Savings
Samsung Display Company today revealed new display technology that features a remarkable power-saving function for mobile electronics, being commercialized for the first time in Galaxy Note 20 Ultra 5G flagship smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005278/en/
Engineers from Samsung Display are using testing devices to inspect frequency changes in display panels that feature adaptive frequency technology (Photo: Business Wire)
The display company has now successfully commercialized its low-power OLED adaptive frequency technology, which can curtail the operating power of a phone’s display by as much as 22 percent over existing smartphones now in general use.
“High-definition video streaming and gaming are expanding their capabilities in line with 5G commercialization, creating a widespread need for display panel technologies that can enable greater power savings,” said Ho-Jung Lee, Vice President of the mobile display product planning team for Samsung Display.
“Our Adaptive Frequency display technology is expected to considerably enhance the user experience by calibrating refresh rates in line with the requirements of a specific application and therein more precisely allocating available power. This will free up time for other smartphone operations,” Lee added.
The company’s power-saving technology allows the display panel to utilize variable refresh rates that consume the least possible amount of power for each type of application. The adaptive frequency technology supports a 120Hz scan rate for playing mobile games that require speedy frame changes, a 60Hz rate for movie streaming, a 30Hz rate for email correspondence, and a 10Hz rate for viewing still images or browsing social networking services.
Existing smartphone panels offer only a fixed refresh rate. They cannot automatically calibrate a phone’s refresh rate, which would result in image flickering caused by luminance differences at lower refresh rates. Samsung Display’s new backplane** technology eliminates flickering for operating frequencies as low as 10Hz.
In particular, when displaying still images, the new variable-rate panel has proven to save 60 percent of operating power by introducing a low-frequency refresh rate of 10Hz, while conventional panels unnecessarily waste power through the use of a consistent, fixed frequency regardless of the type of content.
The world-leading display company also anticipates employing this cutting-edge, power-saving technology with other advanced IT products in the future, to help boost material efficiency and optimize the functionality of operating components.
About Samsung Display
Samsung Display Co., Ltd. is a global leader in display panel market, with OLED and LCD technologies and products. Samsung Display has seven production facilities and five branch sales offices worldwide. The company specializes in high-quality displays for consumer, mobile, IT and industrial usage, including those featuring OLED (organic light emitting diode) and LCD technologies. As a total solution provider, Samsung Display strives to advance the future with next-generation technologies featuring ultra-thin, energy-efficient, flexible, and transparent displays. For more information, please visit www.samsungdisplay.com.
* Refresh or Scan Rate:
The number of frames that a display panel delivers in one second. For example, a 120Hz refresh rate accounts for 120 frame changes. Higher scan rates result in more lively and natural-appearing images.
** Backplane Technology
Making substrates such as glass and polyimide (PI) that are comprised of thin-film transistors (TFTs) required to operate pixels, the minimum unit comprising most display panels.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005278/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)6196-66-3300
Email: ujeong.j@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 10:00:00 EET | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth. “We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Jo
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release
Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom